·
·
Tech & Science
A recent study published on the American Association for the Advancement of Science platform revealed the development of a new chemical compound that showed promising results in suppressing the growth of leukemia cells in preliminary experiments on mice, opening a new horizon for treating this disease.
A recent study published on the American Association for the Advancement of Science platform revealed the development of a new chemical compound that showed promising results in suppressing the growth of leukemia cells in preliminary experiments on mice, opening a new horizon for treating this disease.
The Role of RBPMS Protein in Disease Relapse
Researchers focused on the role of the RBPMS protein in enhancing the survival and regeneration of "leukemic stem cells," which are responsible for the relapse of acute myeloid leukemia after chemotherapy. Analyses showed that high levels of this protein are associated with increased disease severity and poor outcomes, as the protein acts as a coordinator of a chain of reactions that give cancer cells the ability to feed themselves and continue growing.
Effectiveness of Compound "RB98" in Experiments
Researchers were able to design a selective inhibitor of the RBPMS protein, which they named "RB98." Experiments on mouse models proved that this compound reduces the growth of leukemia cells and contributes to prolonging the animals' lifespan. This mechanism relies on preventing the interaction between RBPMS and the IGF2BP3 protein, thereby disrupting a metabolic pathway that the FOXO1 gene depends on to support the survival of cancer cells.
Future Prospects and Warnings
Despite the promising results, the researchers emphasized that the study is still in its early stages, as the results are limited to animal models and cultured cells. They noted that the efficacy and safety of the compound "RB98" in humans have not yet been tested, requiring careful evaluations in future studies to ensure no negative impact on healthy cells.
